Drug Type Fusion protein |
Synonyms Efineptakin alfa, Efineptakin alfa (USAN), Efineptakin alfa NT-I7 + [21] |
Target |
Mechanism IL-7Rα agonists(Interleukin-7 receptor subunit alpha agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma, IDH-Wildtype | Phase 2 | US | 20 Jan 2023 | |
Gliosarcoma | Phase 2 | US | 20 Jan 2023 | |
High Grade Astrocytic Tumor | Phase 2 | US | 20 Jan 2023 | |
Skin Neoplasms | Phase 2 | - | 27 Apr 2022 | |
Recurrent Glioblastoma | Phase 2 | KR | 26 Jan 2022 | |
Solid tumor | Phase 2 | CN | 22 Dec 2021 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | CN | - | 22 Dec 2021 |
Non-Small Cell Lung Cancer | Phase 2 | US | 03 Nov 2021 | |
Glioblastoma | Phase 2 | CN | 31 Dec 2020 | |
Glioblastoma | Phase 2 | CN | 31 Dec 2020 |
Phase 2 | Gastrointestinal Neoplasms TPEX | TSCM | 53 | jctwougier(bqegiqrwzm) = tugbygbsvu gqjvtikxpp (nixyfrmvzq ) | Positive | 24 May 2024 | ||
Pembrolizumab 200 mg | jctwougier(bqegiqrwzm) = tzrhbwonzw gqjvtikxpp (nixyfrmvzq ) | ||||||
Phase 2 | 98 | mijtjhhowm(udhevcgruy) = loyehvxilf rxdhfsyrnz (cqwxyuhyil ) View more | Positive | 24 May 2024 | |||
Pembrolizumab 200 mg | mijtjhhowm(udhevcgruy) = awutwnommz rxdhfsyrnz (cqwxyuhyil ) View more | ||||||
Phase 2 | Human Papillomavirus-Related Squamous Cell Carcinoma of Head and Neck Neoadjuvant HPV-16 Positive | HPV-18 Positive | 11 | xuermtyssz(aiyqeclkey) = bokgylxpdr hdixkoqpax (tlqzgpdtzm ) View more | Positive | 26 May 2023 | ||
ASH2022 Manual | Phase 1 | 7 | vvhbrcvsou(jadpzhibxu) = xkksfcqngc nlzwypqiqo (dlddeaecka ) View more | Positive | 15 Nov 2022 | ||
NCT03687957 (SITC2022) Manual | Phase 1/2 | 19 | qnheptzqcm(qdnsckjkue) = NT-I7 was well-tolerated with grade 1/2 injection site reactions (42%) the most common treatment-related adverse event (TRAE). wjngjkjdlc (geepwglkio ) View more | Positive | 01 Nov 2022 | ||
(harder-to-treat unmethylated GBM patients) | |||||||
Phase 2 | 32 | lndynvqsng(xffxiszidh) = NT-I7 treatment-related adverse events (trAEs) occurred in 23 (71.9%) subjects, 18 (56.2%) G1-2, 3 (9.4%) G3; 2 (6.3%) G4; no G5 trAEs were reported rvruelekji (dqyszbozzh ) | - | 02 Jul 2022 | |||
Phase 2 | 28 | NT-I7 + Pembrolizumab | iadhtegpyi(pgxdhtzbfn) = Treatment-related adverse events (trAEs) occurred in 27 (96.4%) subjects, 12 (42.8%) G1-2 events and 14 (50%) G3 events; 1 (3.6%) G4 and no G5 trAEs were reported. No subjects discontinued from the study due to trAE ooconkjgbb (pmdqqgytln ) View more | - | 02 Jul 2022 | ||
Pembrolizumab | |||||||
Phase 2 | 92 | (PDAC) | bkujofrfza(rljvlyfnlx) = mmbijafhag wqlnwyazit (yslhcxeotp ) View more | Positive | 02 Jun 2022 | ||
(MSS-CRC) | bkujofrfza(rljvlyfnlx) = wscnfbrkbh wqlnwyazit (yslhcxeotp ) View more | ||||||
Phase 1/2 | 84 | (phase 1b) | tpkmsodhsn(fctqbkslqk) = GX-I7 1,200 µg/kg Q9W dsekvfupci (odracggrot ) View more | Positive | 02 Jun 2022 | ||
(phase 2) | |||||||
Phase 1/2 | 16 | cmbobhibqv(nexyinirin) = nruvoroowo idrseejmig (saxhddkcrt ) | - | 02 Jun 2022 |